TNFSF11 and Marchiafava-Bignami disease: Regarding the MBD therapeutics, the current guidelines suggests that bisphosphonates (namely zoledronic acid or pamidronic acid) should be administered to all patients with active MM, regardless of the presence of MBD in imaging study; denosumab, a humanized monoclonal antibody directed against RANKL, is used for patients with MBD on imaging or for patients with renal impairment [11].